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Aims The purpose of the current trial was to test the hypothesis that breathing oxygen-enriched air increases exercise
performance of patients with pulmonary arterial or chronic thrombo-embolic pulmonary hypertension (PAH/
CTEPH) and to investigate involved mechanisms.
...................................................................................................................................................................................................
Methods
and results
Twenty-two patients with PAH/CTEPH, eight women, means ± SD 61 ± 14 years, resting mPAP 35 ± 9mmHg, PaO2
ambient air >7.3 kPa, underwent four bicycle ergospirometries to exhaustion on different days, while breathing
oxygen-enriched (FiO2 0.50, hyperoxia) or ambient air (FiO2 0.21, normoxia) using progressively increased or con-
stant load protocols (with 75% maximal work rate under FiO2 0.21), according to a randomized, sham-controlled,
single-blind, cross-over design. ECG, pulmonary gas-exchange, arterial blood gases, cerebral and quadriceps muscle
tissue oxygenation (CTO and QMTO) by near-infrared spectroscopy were measured. In ramp exercise, maximal
work rate increased from 113 ± 38 W with normoxia to 132 ± 48 W with hyperoxia, mean difference 19.7 (95%
CI 10.5–28.9) W, P< 0.001. Constant load exercise endurance increased from 571 ± 443 to 1242 ± 514 s, mean dif-
ference 671 (95% CI 392–951) s, P< 0.001. At end-exercise with hyperoxia PaO2, CTO, QMTO, and PaCO2 were
increased, and ventilatory equivalents for CO2 were reduced while the physiological dead space/tidal volume ratio
remained unchanged.
...................................................................................................................................................................................................
Conclusion In patients with PAH/CTEPH, breathing oxygen-enriched air provides major increases in exercise performance.
This is related to an improved arterial oxygenation that promotes oxygen availability in muscles and brain and to a
reduction of the excessive ventilatory response to exercise thereby enhancing ventilatory efficiency. Patients with
PAH/CTEPH may therefore benefit from oxygen therapy during daily physical activities and training.
...................................................................................................................................................................................................
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Introduction
The major forms of precapillary pulmonary hypertension (PH), pul-
monary arterial hypertension (PAH) and chronic thrombo-embolic
PH (CTEPH), are characterized haemodynamically by a mean pul-
monary artery pressure (mPAP) of >_25mmHg along with a pulmon-
ary artery wedge pressure (PAWP) of <_15 mmHg at rest.1 PAH and
CTEPH cause dyspnea, impaired exercise performance and are asso-
ciated with reduced quality of life and survival.1–3 The symptoms and
exercise limitation in patients with precapillary PH have been attrib-
uted to several pathophysiologic mechanisms. A typical finding in
PAH/CTEPH is an excessive ventilatory response to exercise associ-
ated with high ventilatory equivalents for oxygen uptake and carbon
dioxide (CO2) output.
4 This has been attributed to an increased che-
mosensitivity, sympathetic nervous system activation and increased
physiological dead space.4,5 Further, an inadequate increase in cardiac
output during exercise causes early lactic acidosis with increased
CO2 production relative to oxygen consumption thereby increasing
respiratory drive and ventilatory requirements.6,7 A low cardiac out-
put also results in a reduced mixed venous oxygen saturation which,
together with right-left shunts through a patent foramen ovale in
some patients, may lead to severe arterial hypoxaemia during exer-
cise that further stimulates ventilation and worsens PH by hypoxic
pulmonary vasoconstriction.7 As a consequence, oxygen delivery to
the muscles, the brain and other organs is reduced thereby limiting
exercise capacity.6,8–10
The treatment of precapillary PH includes pulmonary endarterec-
tomy in selected patients with CTEPH11,12 and PH-targeted medication
or lung transplantation in patients with PAH and post-operatively per-
sisting or inoperable CTEPH and supportive measures such as diuretics
and training.1,13,14 Continuous long-term oxygen therapy is recom-
mended as a supportive measure if resting arterial partial pressure of
oxygen (PaO2) is <8 kPa and when there is symptomatic benefit and
correctable oxygen desaturation during exercise but these recommen-
dations are not based on robust evidence. In a systematic search of the
literature we have identified only one randomized, controlled trial eval-
uating efficacy of oxygen therapy in precapillary PH.15 It revealed
that one week of nocturnal supplemental oxygen therapy improved
the 6-minute walk distance (6MWD) in patients with PAH/CTEPH in
comparison to sham-oxygen therapy. Since oxygen therapy is widely
used as an adjunct to medical therapy in PAH/CTEPH-patients further
studies evaluating its efficacy are needed. The purpose of the current
randomized, sham-controlled trial was therefore to test the hypothesis
that breathing oxygen-enriched air (FiO2=0.50) increases exercise
performance of patients with PAH or CTEPH, and to evaluate the
involved physiological mechanisms.
Methods
Study design
This randomized, sham-controlled, single-blinded, cross-over trial
comprises two consecutive test sequences evaluating efficacy of
hyperoxia in improving exercise performance in patients with PAH
or CTEPH using progressive or constant load exercise protocols, re-
spectively. Participants gave written informed consent. The study was
approved by the institutional ethics committee (KEK 2012-0251) and
registered at ClinicalTrials.gov (NCT01748474).
Participants
Consecutive patients seen at our clinic between June 2014 and
January 2015 with PAH or CTEPH diagnosed according to current
guidelines,1 who were stable on PH-targeted drug therapy and had a
resting PaO2 >_7.3 kPa but arterial oxygen desaturation during exer-
cise were invited to participate. The diagnosis was based on a compat-
ible history and right heart catheterization showing a mPAP >_25
mmHg, a PAWP <_15 mmHg. A thorough evaluation including history,
ECG, echocardiography, thoracic computed tomography, ventilation
perfusion scan, pulmonary angiography, blood tests for liver function,
HIV and rheumatic diseases were performed as appropriate to con-
firm the diagnosis and classify PH. Patients with left heart or lung
disease-associated PH, miscellaneous forms, resting PaO2 <7.3 kPa,
unstable condition or contraindication for ergometry were excluded.
Interventions
Patients underwent four cycle exercise tests, on four separate occa-
sions, a few days apart. The first two tests were performed with a
progressive ramp protocol to exhaustion with work rate increments
of 10–20 W/min to achieve an exercise duration of 8–12 min, cycling
rate was 50–60 rpm.16 Patients were breathing either ambient air
(normoxia, FiO2 0.21) or oxygen-enriched air (hyperoxia, FiO2 0.50),
in randomized order. They breathed through a mouthpiece con-
nected to the flow sensor of a metabolic unit (Ergostick, Geratherm
Medical, Gschwenda, Germany) and a two-way valve (Hans Rudolph,
Shawnee, USA). The inlet of the valve was connected to a gas-mixing
device set to provide either normoxia or hyperoxia (Altitrainer,
Nyon, Switzerland). The second two exercise tests were performed
with constant load to exhaustion at 75% of individual maximal work
rate (Wmax) achieved during normoxia. Using the same equipment as
for ramp tests, patients were breathing normoxia or hyperoxia in
randomized order.
Assessments
At the screening visit, the World Health Organization functional class
(WHO-FC) was recorded, and a clinical examination, 6MWD test
and spirometry were performed.
During exercise tests respiratory gas exchange was recorded with
the metabolic unit calibrated before each test. Breath-by-breath val-
ues for minute ventilation (V 0E), breath rate, tidal volume, CO2 out-
put (V 0CO2), and derived variables were recorded. Oxygen uptake is
not reported for tests with hyperoxia because accuracy of the O2-
sensor outside the calibration range of FO2 0.16–0.21 could not be
verified. Heart rate was derived from a 4-lead ECG, blood pressure
by automated arm-cuff measurements. Finger pulse oximetry (SpO2)
and regional tissue oxygenation of the brain and quadriceps muscle
were also recorded. To this end, a near-infrared-spectroscopy sensor
(Hamamatsu, NIRO-200NX, Shizuoka, Japan) was attached with ad-
hesive tape high on the forehead to record cerebral tissue oxygen
saturation (CTO) as ratio of oxygenated/(oxygenatedþ deoxygen-
ated) haemoglobin concentrations in per cent. A second sensor
placed parallel to the long axis of the right vastus lateralis, mid-
distance between the great trochanter and the lateral epicondyle, re-
corded quadriceps muscle tissue oxygen saturation (QMTO).17–19
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Physiologic variables were recorded breath-by-breath and aver-
aged over successive 30-s intervals. Maximal physiologic variables
(end-exercise) were defined as mean values over the final 30 s of ex-
ercise. The ventilatory equivalent for V 0CO2 was calculated as V 0E/
V 0CO2 at end-exercise and as slope over the entire duration of ramp
exercise.20 The physiological dead space fraction (VD/VT) was com-
puted from arterial and expiratory PCO2.
16 To illustrate effects of
hyperoxia on the ventilatory efficiency, V 0E/V 0CO2 ratios were plot-
ted vs. corresponding values of PetCO2. The rearranged alveolar gas
equation (V 0E/V 0CO2 = a/PetCO2*(1-VD/VT) was fitted to these data
points (a = constant).21 Heart rate reserve was calculated as 220
minus age minus heart rate at end-exercise; ventilatory reserve as
40xFEV1 minus V 0E at end-exercise. Reference values for Wmax and
V 0O2max were those of Glaser et al.
22
Assessed for eligibility (n= 40) 
Excluded (n=17) 
6 PaO2 < 7.3 kPa 
4    musculo-skeletal limitations 
4    recent changes in medication 
3    WHO functional class IV
Progressive ramp exercise with 
normoxia (FiO2 0.21) 
n=12 
Randomized 
n=23
1 withdrew consent
Progressive ramp exercise with 
hyperoxia (FiO2 0.50) 
n=10 
Progressive ramp exercise with 
hyperoxia (FiO2 0.50) 
n=12 
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Figure 1 Study design with patient flow in trials with progressive ramp exercise (Trial 1) and constant load exercise (Trial 2) at 75% of maximal
work rate achieved with room air. Blue and red frames mark trials with FiO2 0.21 and 0.50, respectively.
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Outcomes and sample size
Primary outcomes were the change in Wmax during progressive ramp
tests (trial 1) and the change in endurance during constant load tests
(trial 2) induced by hyperoxia vs. normoxia, respectively. To our
knowledge, the minimal important difference in Wmax during submax-
imal exercise has not been determined for patients with PH.
Therefore, according to clinical experience, we assumed a difference
in Wmax of 10 W (with a SD of 12 W for repeated tests) or an effect
size of at least 0.8 (large) as clinically important.23,24 Based on these
premises we aimed at including at least 20 participants accounting for
possible dropouts to achieve a power of 0.9 (alpha 0.05). Secondary
outcomes were physiologic variables at end-exercise and at corres-
ponding submaximal workloads (isoload/isotime).
Randomization and blinding
Randomization was performed by letting participants draw a sealed
envelope from a set of envelopes containing balanced test sequences.
Participants were blinded to the inhaled oxygen concentration.
Data analysis and statistics
Data are summarized as means ± SD. As the main purpose of the
study was to evaluate efficacy of hyperoxia in enhancing performance
of patients applying this treatment during exercise, the primary ana-
lysis was performed according to the per protocol principle in partici-
pants completing corresponding tests both in normoxia and
hyperoxia; an intention to treat analysis is also presented for the main
outcomes conservatively assuming zero difference in outcomes be-
tween both conditions. Data from tests with hyperoxia were com-
pared with those with normoxia in terms of the mean difference and
95% confidence intervals. Data from progressive workloads during
both ramp tests were compared by computing means over succes-
sive fractions of maximal exercise time during normoxia, i.e. over the
periods from 1–10%, 11–20%, etc., up to 91–100% exercise time in
normoxia, and over identical time periods in tests with hyperoxia.
Data from constant load tests in hyperoxia and normoxia were com-
pared at end-exercise and at isotimes. Isotime refers to the time
under hyperoxia that corresponds to the time of end-exercise under
normoxia. Linear regression analyses were used to explore whether
physiologic changes induced by hyperoxia were correlated with pa-
tient characteristics. Variables that were significant in univariate ana-
lysis were entered into a multivariate analysis. Significance was
assumed at P< 0.05.
Results
Patients
The patient flow is shown in Figure 1. Twenty-three patients were
randomized, one of them withdrew consent before undergoing any
test; five participants completing ramp tests refused to participate in
subsequent constant load tests because of lack of time. Therefore,
data from ramp tests were available for in 22 patients, data from con-
stant load tests in 17 patients. Patients were in WHO-FC 2 or 3, mean
resting mPAP was 35 ± 9 mmHg, resting SpO2 was 95 ± 3% (Table 1).
Progressive ramp tests under normoxia
and hyperoxia
Table 2 and Figures 2–4 summarize the results of maximal ramp tests.
In normoxia Wmax was moderately reduced compared with pre-
dicted normal values (113 ± 38 W, 71 ± 18% predicted). Hyperoxia
increased Wmax significantly to 132 ± 48 W, corresponding to a mean
change (95% CI) of þ19.7 (10.5 to 28.9) W, P< 0.001 (Figure 2) and
Table 1 Patient characteristics
Number of participants (female) 22 (8)
Age, years 61 ± 14
Body mass index, kg/m2 27.1 ± 6.0
New York Heart association functional
class (II, III)
11 (50%), 11 (50%)
6-min walk distance, m 540 ± 83
SpO2 at rest, % 95 ± 3
SpO2 at end of 6-min walk, % 89 ± 5
Classification
Pulmonary arterial hypertension 11 (50%)
 Idiopathic 8 (36%)
 Connective tissue disease related 2 (9%)
 Porto-pulmonary 1 (5%)
Chronic thrombo-embolic pulmonary
hypertension
11 (50%)
Treatment
Endothelin receptor antagonist 9 (41%)
Phosphodiesterase-5-inhibitor 5 (23%)
Soluble guanylate-cyclase simulator 4 (18%)
Combination therapy 2 (9%)
Nocturnal oxygen therapy 1 (5%)
Right heart catheter data and systemic
blood pressure
Mean pulmonary artery pressure, mmHg 35 ± 9
Pulmonary artery wedge pressure, mmHg 11 ± 3
Right atrial pressure, mmHg 8 ± 4
Cardiac index, l/min/m2 2.9 ± 0.6
Pulmonary vascular resistance, WU 4.7 ± 2.5
Mixed venous oxygen saturation, % 68 ± 5
Heart rate, bpm 80 ± 18
Systemic blood pressure, systolic 128 ± 16
and diastolic, mmHg 79 ± 9
Lung function
Forced expiratory volume in 1 s (FEV1),
% predicted
91 ± 21
Forced expiratory volume (FVC), % predicted 97 ± 23
FEV1/FVC 76 ± 7
Total lung capacity, % predicted 95 ± 16
Diffusion capacity for carbon dioxide,
% predicted
69 ± 22
Ramp protocol
10, 15, 20, 25 W/min, n 10/11/0/1
Date are presented as mean ± SD, numbers and per cent
SpO2, pulse oximetry.
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thus 18 (8 to 29)%. 16/22 patients (73%) increased Wmax by >_5%, 13/
22 patients (59%) by >_10%. Compared with normoxia, maximal
heart rate and V 0CO2 were higher under hyperoxia while V 0E was un-
changed so that V 0E/V 0CO2 at end-exercise and the V 0E/V 0CO2 slope
were significantly reduced (Table 2, Figures 2 and 3). To further ex-
plore the mechanisms responsible for the improved ventilatory effi-
ciency pairs of V 0E/V 0CO2 ratios at end-exercise during tests under
normoxia and hyperoxia, respectively, were plotted vs. the corres-
ponding pairs of end-tidal PCO2. This analysis revealed that hyper-
oxia shifted the V 0E/V 0CO2 ratio to a more favourable position on
the line defined by the rearranged alveolar gas equation (Figure 3). As
VD/VT ratios were similar under normoxia and hyperoxia (Table 2)
the V 0E/V 0CO2 ratios were reduced mainly by the higher alveolar
PCO2 rather than by a reduction in VD/VT. Hyperoxia increased
SpO2 and both the CTO and QMTO at maximal exercise. Arterial
blood gas analysis at maximal exercise revealed a major increase in
SaO2 and PaO2 but a lower pH and a higher PaCO2 under hyperoxia
vs. normoxia (Table 2). There was a trend towards reduced dyspnea
at end-exercise while leg fatigue was perceived as similar under
hyperoxia and normoxia (Figure 2). An intention to treat analysis
including all randomized patients and entering 0 difference for missing
values revealed principally the same results as the per protocol ana-
lysis, i.e. a mean increase in Wmax by hyperoxia vs. normoxia of 18.8
W (95% CI 9.9–27.8, P< 0.001).
Comparisons of variables during progressive ramp exercise at cor-
responding submaximal isoloads (Figure 4) revealed that hyperoxia was
associated with lower heart rates, V 0E and V 0CO2 compared with nor-
moxia. A drop in SpO2 towards end of exercise was prevented by
hyperoxia and a drop in CTO was delayed until near maximal exercise.
Univariable linear regression analysis revealed that only male sex
(coefficient 18.6, 95% CI 0.9–36.2, P= 0.040) and the 6MWD (coeffi-
cient 0.13, 95% CI 0.03–2.3, P= 0.012) were significantly correlated
with the increase in Wmax under hyperoxia (Supplementary material
online, Table S1). No such correlation existed for various other
....................................................................................................................
....................................................................................................................................................................................................................
Table 2 Maximal ramp bicycle exercise under normoxia and hyperoxia
Ambient air
FiO2 0.21,
Normoxia
Oxygen enriched air, FiO2 0.50, Hyperoxia
End-exercise Isotime corresponding
to end-exercise time
under normoxia
P-value End-exercise P-value
Work rate, W 113 ± 38 113 ± 38 NA 132 ±48 <0.001
Work rate, % predicted Wmax 71 ± 18 71 ± 18 81 ±19 <0.001
Endurance, s 432 ± 111 432 ± 111 NA 525 ±136 0.001
Heart rate, bpm 130 ± 8 125 ± 18 <0.001 136 ±21 <0.001
Heart rate reserve, bpm 27 ± 20 35 ± 19 <0.001 22 ±19 <0.001
Minute ventilation (V 0E), l/min 62 ± 17 53 ± 13 <0.001 65 ±18 0.315
Breathing reserve, % MVV 42 ± 15 51 ± 14 0.001 40 ±12 0.504
Tidal volume, l 2.1 ± 0.7 2.1 ± 0.7 0.414 2.1 ±0.7 0.498
Breath rate, 1/min 32 ± 10 27 ± 10 <0.001 32 ±11 0.781
Oxygen uptake (V 0O2), l/min 1.4 ± 0.4 NA NA NA NA
V 0O2, % predicted 75 ± 15
Carbon dioxide output (V 0CO2). l/min 1.5 ± 0.5 1.5 ± 0.4 0.214 1.8 ± 0.6 <0.001
V 0E/V 0CO2 slope 42.3 ± 10.6 NA NA 36.2 ± 9.2 <0.001
V 0E/V 0CO2 at end-exercise 40.8 ± 8.7 35.7 ± 6.5 <0.001 36.9 ± 7.4 <0.001
Death-space fraction (VD/VT) 0.40 ± 0.12 NA NA 0.42 ± 0.09 0.310
End-tidal PCO2, kPa 3.9 ± 0.8 4.4 ± 0.8 <0.001 4.4 ± 1.1 <0.001
Pulse oximetry (SpO2), % 90 ± 6 99 ± 1 <0.001 98 ± 2 <0.001
Cerebral tissue SO2, (CTO), % 61 ± 9 72 ± 7 0.001 71 ± 7 0.002
Quadriceps SO2, (QMTO), % 61 ± 8 65 ± 10 0.001 65 ± 11 0.002
Arterial pH 7.38 ± 0.05 NA NA 7.32 ± 0.04 <0.001
PaO2, kPa 8.8 ± 2.5 NA NA 32.1 ± 7.3 <0.001
PaCO2, kPa 4.8 ± 0.6 NA NA 5.4 ± 0.7 0.001
SaO2, % 89.9 ± 7.9 NA NA 99.4 ± 1.0 0.001
Arterial lactate, mmol/l 4.8 ± 2.1 NA NA 5.4 ± 2.1 0.522
Arterial bicarbonate, mmol/l 21.3 ± 1.9 NA NA 21.1 ± 1.9 0.950
Borg CR10 dyspnea score 5.8 ± 2.0 NA NA 5.1 ± 1.9 0.064
Borg CR10 Leg discomfort score 3.7 ± 2.4 NA NA 4.2 ± 2.3 0.459
Means ± SD, n= 22, primary outcome in bold. Individual values were averaged over 30 s; in tests with oxygen enriched air (FiO2 0.50) isotime refers to the time of end-exercise
in normoxia (FiO2 0.21).
MVV, maximal voluntary ventilation; SaO2, arterial oxygen saturation by co-oximetry; NA, not available.
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physiologic variables and the PH class (PAH, CTEPH). In multivariable
regression analysis including sex and 6MWD, only 6MWD remained
a significant predictor of the increase in Wmax under hyperoxia (coef-
ficient 0.11, 95% CI 0.01–0.21, P = 0.038) (Supplementary material
online, Table S1).
Constant load exercise under hyperoxia
vs. normoxia
Constant load at 75% Wmax (normoxia) corresponded to a work rate
of 86 W (range 50–155). Hyperoxia increased endurance from a mean
value of 571 s in normoxia to 1242 s, i.e. a value more than twice as
Figure 2 Changes in exercise variables induced by hyperoxia. Mean differences in corresponding variables measured during hyperoxia minus nor-
moxia with 95% confidence intervals are displayed for progressive ramp exercise (blue circles and lines) and for constant load exercise (green
squares and lines). Positive differences correspond to greater values during tests with hyperoxia. V 0CO2=CO2 output; V 0E/V 0CO2 =ventilatory
equivalent for V 0CO2 at end-exercise.
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long (mean increase 671 s, 95% CI 392–951, P< 0.001, Figure 2, Table
3). Under hyperoxia 15/17 patients increased their exercise time
by >5% and 10/17 by >50%. V 0CO2 at end-exercise under hyperoxia
was similar to corresponding values under normoxia, but V 0E/V 0CO2
at end-exercise was reduced by hyperoxia in association with a lower
V 0E (Table 3, Figure 2). Arterial blood gas analysis at end-exercise re-
vealed higher values of PaO2, SaO2 and PaCO2 under hyperoxia than
normoxia but lower lactate concentrations (Table 3, Figure 2). The VD/
VT ratio was unchanged by hyperoxia. An intention to treat analysis
including all randomized patients and entering 0 difference for missing
values revealed principally the same results as the per protocol analysis,
i.e. a major increase in endurance by hyperoxia vs. normoxia of 515 s
(95% CI 260–770, P< 0.001). SpO2 and CTO were both higher under
hyperoxia at isotime and end-exercise, whereas QMTO was not signifi-
cantly different at isotime under hyperoxia compared with end-
exercise normoxia. Despite the prolonged exercise time under hyper-
oxia, patients perceived significantly less dyspnea at end-exercise than
under normoxia (Figure 2, Table 3); Borg scores of leg discomfort did
not differ from values under normoxia.
The increase in endurance with hyperoxia was not significantly
correlated with any of the physiologic variables tested, nor with sex
or 6MWD (Supplementary material online, Table S2).
Discussion
The results of the current randomized, sham-controlled, single-blind,
cross-over trial in patients with PAH or CTEPH demonstrate that
breathing oxygen-enriched air significantly enhanced exercise per-
formance in terms of Wmax in ramp exercise tests and endurance in
submaximal constant load tests. These improvements were associ-
ated with a higher PaCO2 at end-exercise, and a reduced V 0E/V 0CO2
ratio, while the VD/VT ratio remained unchanged. These findings
were consistent with a reduction in excessive ventilatory drive by
hyperoxia that reduced the ventilatory requirement for CO2 output.
Since hyperoxia led to a higher arterial, cerebral and quadriceps oxy-
gen saturation it may have enhanced exercise performance by pro-
moting availability of oxygen in working muscles and in cerebral
motor and sensory neurons while reducing dyspnea perception des-
pite the higher intensity and longer duration of exercise.
The current trial is the first to provide robust, quantitative evi-
dence of the efficacy of breathing oxygen-enriched air in improving
exercise performance in patients with PAH/CTEPH. The most im-
pressive effect was observed in tests with submaximal constant load
where the endurance was increased more than twice over control
values during normoxia. But hyperoxia also increased Wmax consider-
ably (by 18%). These improvements achieved in patients who were
already on PH-targeted medication seem quite relevant for daily life.
They support the use of oxygen as an adjunctive therapy during
everyday activities.1 The increases in exercise performance by hyper-
oxia we observed in PAH/CTEPH patients with a near normal PaO2
at rest but exercise-induced oxygen desaturation in normoxia
exceed those achieved by hyperoxia in healthy volunteers (i.e. 5%
increase in Wmax) showing only minimal exercise-induced desatur-
ation.25 Thus, the beneficial effect of hyperoxia might be enhanced
when there is exercise-induced hypoxaemia in normoxia.
Our data suggest that several mechanisms contributed to the im-
provements in exercise performance of PAH/CTEPH patients by
hyperoxia. A characteristic finding in PAH/CTEPH patients is hyper-
ventilation at rest and an excessive ventilatory response to exer-
cise.4,6 This has been attributed to increased physiological dead space
related to ventilation of lung areas that are poorly perfused due to
vessel obliteration and remodelling.26 However, increased peripheral
and central chemosensitivity seems to be another important cause of
increased ventilation that may be of particular relevance in PAH/
CTEPH patients with severe exercise-induced hypoxaemia due to
pulmonary ventilation/perfusion mismatch and right-left shunts
through a patent foramen ovale in some patients.27,28 The increased
PaCO2 at end-exercise together with an unchanged VD/VT ratio
observed in the current study are consistent with the notion that
breathing oxygen-enriched air reduced V 0E by reducing hypoxic
stimulation of peripheral chemoreceptors. The consecutive rise in
PaCO2 and PetCO2 shifted the V 0E/V 0CO2 vs. PetCO2 relationship
to lower ventilatory equivalents for V 0CO2. More favourable V 0E/
V 0CO2 vs. PetCO2 relationships were also found in healthy individ-
uals compared with patients with PAH or heart disease known to
have an enhanced ventilatory drive.21 In the current study, the un-
changed V 0E despite a greater V 0CO2 during progressive ramp tests
in hyperoxia and the reduced V 0E at similar V 0CO2 during constant
load tests in hyperoxia are consistent with a reduction in excessive
ventilatory drive as VD/VT remained constant.
Figure 3 Plot of individual ventilatory equivalents for V 0CO2
(V 0E/V 0CO2) vs. corresponding PetCO2 at end of ramp exercise.
Changes induced by hyperoxia are represented by blue lines that
start from values measured in normoxia and end in values measured
in hyperoxia (FiO2 0.50, red circles). Hyperoxia shifted the V 0E/
V 0CO2 vs. PetCO2 ratio to more favourable, lower values of V 0E/
V 0CO2 along the long-dashed and short-dashed grey lines that rep-
resent least square fits of the rearranged alveolar gas equation
through data points from tests with hyperoxia and normoxia, re-
spectively [V 0E/V 0CO2=a/(PetCO2 *(1-VD/VT)]. As VD/VT ratios
were similar in hyperoxia and normoxia the two regression lines
are nearly superimposed and the greater ventilatory efficiency in
hyperoxia is related mainly to a reduced respiratory drive with
higher values of the alveolar and end-tidal PCO2.
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Hyperoxia was also associated with a lower heart rate at submaxi-
mal isoloads/isotimes compared with normoxia presumably related to
modulation of the cardiac autonomic control by hyperoxia towards a
reduction of the sympathetic overexcitation that has been described
in PAH patients5 and in healthy individuals exposed to hypoxia.29
Increasing the arterial PaO2 by hyperoxia may also have contrib-
uted to improved exercise performance by reducing pulmonary vas-
cular resistance and by preventing the exercise-induced drop in
arterial oxygen saturation that occurs as a consequence of an
inadequate rise in cardiac output and a low mixed venous oxygen sat-
uration in PAH/CTEPH patients. Consequently, the exercise-induced
fall in cerebral and muscle tissue oxygenation was also mitigated and
delayed by hyperoxia. This might have reduced dyspnea and
enhanced the ability of the muscles to perform aerobic work. Thus,
during submaximal constant load exercise, the lactate concentration
at end-exercise was lower with hyperoxia than normoxia and per-
ceived dyspnea was also lower despite a much longer duration of ex-
ercise compared with normoxia. During progressive ramp exercise
Figure 4 Physiological changes during progressive ramp exercise with blue circles and lines representing normoxia and red circles and lines repre-
senting hyperoxia (FiO2 0.50). The values represent means (±SD) over successive 10% increments of maximal workload (Wmax) under normoxia, i.e.
1–10%, 11–20% of Wmax normoxia, etc. The last values (max) represent mean values over the final 30 s end-exercise which occur at a later time with
hyperoxia than normoxia.*P< 0.05 FiO2 0.50 vs. FiO2 0.21.
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..with hyperoxia, a higher Wmax was achieved than with normoxia but
lactate concentrations were similar in both conditions.
The relative contribution of the improved oxygen delivery to the
brain, heart and working muscles resulting in a better tissue oxygen-
ation, the enhanced ventilatory efficiency and the improved cardiac
response reflected by the lower heart rate at isoload under hyper-
oxia cannot be quantified by our results. The present study includes a
limited number of patients with relatively mild PAH/CTEPH and
some of them did not undergo constant load exercise tests which
limits the generalizability of our results to all PH-patients.
In conclusion, our randomized, sham-controlled trial quantifies for
the first time the improvements in exercise performance that can be
achieved in PAH/CPETH patients by breathing oxygen-enriched air.
Our findings suggest that hyperoxia enhances both maximal cycling
performance and endurance in performing submaximal work. It
exerts these effects by improving oxygen saturation in the arterial
blood, brain and working muscles and by reducing the augmented
chemosensitivity that leads to an excessive ventilatory response to
exercise. Therefore, our data support the use of oxygen
supplementation by patients with PAH/CTEPH during daily activities
or training as it may allow them to perform higher levels of physical
exercise over a longer duration and reduce dyspnea. The findings ex-
pand those from our previous, randomized trial that demonstrated
an increase in the 6 min walk distance by nocturnal oxygen supple-
mentation in PAH/CTEPH patients.15 Further studies should evalu-
ate the effects of long-term oxygen therapy in patients with
precapillary PH.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Table 3 Constant load bicycle exercise at 75%Wmax under normoxia and hyperoxia
Ambient air,
FiO2 0.21,
Normoxia
Oxygen enriched air, FiO2 0.50 Hyperoxia
End-exercise Isotime corresponding
to end-exercise time
under normoxia
P-value End-exercise P-value
Endurance, s 571 ± 443 571 ± 443 NA 1242 ± 514 <0.001
Work rate, W 86 ± 28 86 ± 28 NA 86 ± 28 NA
Heart rate, bpm 138 ± 17 126 ± 17 0.002 132 ± 16 0.063
Heart rate reserve, bpm 23 ± 17 34 ± 16 0.002 29 ± 17 0.066
Minute ventilation (V 0E, l/min) 65 ± 19 54 ± 13 0.015 60 ± 13 0.216
Breathing reserve, % MVV 37 ± 17 46 ± 18 0.107 41 ± 18 0.461
Tidal volume, l 1.8 ± 0.7 1.9 ± 0.7 0.464 1.8 ± 0.6 0.825
Breath rate, 1/min 37 ± 10 31 ± 13 <0.001 36 ± 13 0.274
Oxygen uptake (V 0O2), l/min 1.4 ± 0.4 NA NA NA NA
V 0O2% predicted 88 ± 49 NA NA NA NA
Carbon dioxide output (V 0CO2), l/min 1.4 ± 0.5 1.4 ± 0.4 0.855 1.5 ± 0.4 0.285
V 0E/V 0CO2 at end-exercise 45.8 ± 8.7 37.4 ± 5.7 <0.001 39.6 ± 6.9 <0.001
Death space fraction (VD/VT) 0.47 ± 0.09 NA NA 0.44 ± 0.09 0.170
End-tidal PCO2, kPa 3.5 ± 0.6 4.2 ± 0.6 <0.001 4.0 ± 0.8 <0.001
Pulse oximetry (SpO2), % 88.8 ± 6.9 98.6 ± 1.1 <0.001 98.7 ± 0.9 <0.001
Cerebral tissue SO2, % 62.0 ± 9.2 68.7 ± 7.5 0.003 68.6 ± 8.1 0.006
Quadriceps SO2, % 61.3 ± 9.0 65.0 ± 10.3 0.312 66.4 ± 0.4 0.021
Arterial pH 7.35 ± 0.06 NA NA 7.35 ± 0.07 0.379
PaO2, kPa 7.6 ± 1.7 NA NA 32.6 ± 6.7 <0.001
PaCO2, kPa 4.5 ± 0.6 NA NA 5.2 ± 0.8 0.012
SaO2, % 88.2 ± 5.3 NA NA 99.4 ± 0.7 <0.001
Arterial lactate, mmol/l 6.2 ± 1.9 NA NA 4.2 ± 2.3 0.001
Arterial bicarbonate, mmol/l 19.4 ± 2.1 NA NA 21.1 ± 3.1 0.020
Borg CR10 dyspnea 5.5 ± 2.1 NA NA 3.8 ± 2.1 0.002
Borg CR10 leg discomfort 3.8 ± 2.0 NA NA 3.7 ± 2.7 0.924
Means ± SD, n= 17, primary outcome in bold. Individual values were averaged over 30 s; in tests with oxygen enriched air (FiO2 0.50) isotime refers to the time of end-exercise
in normoxia (FiO2 0.21).
MVV, maximal voluntary ventilation; SaO2, arterial oxygen saturation by co-oximetry; NA, not available.
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